Vaginal Dryness, UTIs, and the Estrogen Connection No One Talks About

A woman in her late 40s or 50s develops recurrent urinary tract infections. She takes antibiotics. The infection clears. It returns weeks later. She takes another course. The cycle continues. No one asks about her hormonal status.

Another woman notices vaginal dryness that makes intimacy uncomfortable. She buys lubricant. It helps temporarily. The dryness persists. She assumes this is what aging feels like and adjusts her expectations.

A third woman experiences urinary urgency, a sudden and compelling need to urinate that was never there before. She is prescribed a bladder medication. It helps modestly. The urgency persists.

All three women have the same underlying condition, and it is not urological or infectious. It is hormonal.

Genitourinary Syndrome of Menopause

In 2014, the International Society for the Study of Women’s Sexual Health and the North American Menopause Society jointly introduced the term “genitourinary syndrome of menopause” (GSM) to describe the constellation of vulvovaginal and urinary symptoms caused by estrogen decline.

GSM encompasses vaginal dryness, burning, irritation, and pain with intercourse, as well as urinary urgency, frequency, recurrent UTIs, and dysuria (painful urination). The condition affects an estimated 50 to 70 percent of postmenopausal women, though prevalence is likely underreported because many women do not raise these symptoms with their physicians.

Unlike hot flashes, which often improve over time, GSM is progressive. Without treatment, the symptoms worsen as the tissue continues to atrophy. For a broader view of how estrogen decline affects the body during this transition, see our menopause overview.

Why Estrogen Matters to These Tissues

The vaginal epithelium, the urethral mucosa, the bladder trigone, and the pelvic floor musculature are all estrogen-dependent tissues. Estrogen receptors are dense throughout the lower urogenital tract. When estrogen levels are adequate, these tissues are thick, well-vascularized, elastic, and lubricated. The vaginal pH is maintained in an acidic range (3.5 to 4.5) that supports a healthy lactobacillus-dominant microbiome and suppresses pathogenic bacteria.

When estrogen declines, the vaginal epithelium thins from approximately 40 cell layers to fewer than 10. Blood supply diminishes. Lubrication decreases. The vaginal pH rises toward neutral (6.0 to 7.0), which shifts the microbiome away from protective lactobacilli toward organisms like E. coli and group B streptococcus. This shift reflects not just a change in local tissue quality but a broader pattern of declining tissue resilience that characterizes the postmenopausal state. The tissues lose their capacity for self-defense at the same time that systemic metabolic capacity is declining, creating a state of generalized vulnerability to infection and inflammation.

The urethral mucosa undergoes parallel changes. The mucosal barrier thins, the urethral closure pressure drops, and susceptibility to urinary pathogens increases. The recurrent UTIs are not caused by inadequate hygiene or insufficient cranberry consumption. They are caused by tissue that no longer has the structural and immunological integrity to defend itself. This tissue-level decline is inseparable from the broader metabolic decline that characterizes perimenopause and menopause.

The Cycle of Antibiotics

Many women with recurrent UTIs in the perimenopausal and postmenopausal years receive repeated antibiotic courses. This approach treats the infection but not the cause of the recurrence. Each course of antibiotics further disrupts the vaginal and urinary microbiome, which can paradoxically increase susceptibility to the next infection.

A Cochrane review found that vaginal estrogen therapy significantly reduced the recurrence of UTIs in postmenopausal women compared to placebo. The mechanism is restoration of the vaginal epithelium, normalization of vaginal pH, and recolonization with protective lactobacilli.

Estrogen therapy addresses the tissue environment that makes recurrent infection possible. Antibiotics address the infection once it has occurred. The distinction between treating the cause and treating the consequence is the difference between resolution and recurrence.

Local Estrogen Therapy

Vaginal estrogen is the first-line treatment for GSM. It is available as a cream, tablet, ring, or compounded preparation, all of which deliver estradiol directly to the affected tissue with minimal systemic absorption.

The doses used in vaginal estrogen therapy are a fraction of those used in systemic hormone therapy. The concern about breast cancer risk that accompanies systemic estrogen discussions does not apply at the same magnitude to local vaginal application. The North American Menopause Society, the American College of Obstetricians and Gynecologists, and multiple international menopause societies have published position statements supporting the safety of vaginal estrogen, including in women with a history of breast cancer (though this requires case-by-case discussion with their oncologist).

Many women who are hesitant about systemic hormone therapy are comfortable with vaginal estrogen once they understand the local nature of the treatment and the minimal systemic exposure.

What to Expect

Improvement in vaginal dryness and comfort typically begins within 2 to 4 weeks of initiating local estrogen therapy. Tissue thickening, improved lubrication, and normalization of vaginal pH develop over 4 to 12 weeks. Urinary symptoms, including urgency and recurrent UTI frequency, improve on a similar timeline.

The treatment is ongoing. GSM recurs when estrogen therapy is discontinued, because the underlying estrogen deficiency persists. Many women use vaginal estrogen indefinitely as part of their long-term health maintenance.

When Systemic Estrogen Is Also Indicated

Women experiencing GSM alongside vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, or cognitive symptoms may benefit from systemic estrogen therapy in addition to, or instead of, local treatment alone.

Systemic transdermal estradiol, delivered via patch, gel, or cream, provides both the systemic benefits (cardiovascular, skeletal, neurological) and sufficient circulating estrogen to support urogenital tissue health. Some women on systemic therapy still require supplemental local estrogen for optimal urogenital results, as the tissue-level concentrations needed for full restoration may exceed what systemic therapy alone provides.

The treatment plan is individualized based on the patient’s full symptom profile, risk factors, and preferences.

Why Women Do Not Raise These Symptoms

GSM is underdiagnosed in large part because women do not disclose their symptoms. Cultural discomfort with discussing vaginal and urinary health, the assumption that these changes are an inevitable and untreatable consequence of aging, and the absence of physician-initiated screening all contribute.

Physicians do not routinely ask about vaginal dryness, sexual comfort, or urinary symptoms during annual visits. When patients raise these concerns, the connection to estrogen deficiency is not always made, particularly if the patient is still menstruating (perimenopausal GSM is common) or if the physician is unfamiliar with the condition.

The result is that millions of women live with a treatable condition for years or decades because neither party raises it.

A Condition That Responds to Treatment

GSM is among the most gratifying conditions to treat because the response to estrogen therapy is reliable, measurable, and often transformative. Women who have endured years of discomfort, repeated antibiotics, and diminished sexual function frequently report significant improvement within weeks of starting treatment.

At Manus Solis, urogenital symptoms are assessed as part of the Sensus evaluation. Local and systemic estrogen needs are determined through the Pulsus panel and clinical assessment. The treatment is incorporated into the broader hormonal optimization protocol and monitored over time.

If these symptoms describe your experience, know that they are common, they are caused by a specific hormonal deficit, and they respond well to treatment. The conversation is worth having.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Perimenopause: The Symptoms Most Women Don’t Recognize
• BHRT After Hysterectomy: What Changes and What Doesn’t
• Hormone Therapy and Breast Cancer Risk

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario pharmacy partner. To learn more or book a virtual consultation, visit manussolis.ca.